ABSTRACT: Genome-wide association study of cases of tuberculosis from St Petersburg and Samara, in Russia, compared to healthy controls from the same two cities. Genotype data from Affy6 array.
Project description:Transcription profiling by array of mouse soft tissue sarcoma samples induced by conditional mutations of Kras and p53 against healthy muscles from mice of the same genotype but no induced sarcoma
Project description:The expression of the long non-coding RNAs (lncRNAs) in the active tuberculosis patients,multidrug-resistant tuberculosis patients,cured tuberculosis subjects and healthy controls were scanned using lncRNA microarray.The Arraystar Human LncRNA Microarray version 4.0 (Agilent Technologies) was used,containing 40173 lncRNA probes and 20730 mRNA probes for the detection of lncRNAs and mRNAs in the sample. Non-coding RNAs and mRNAs profiling by array
Project description:DNA Methylation was analyzed in tuberculosis patients without HIV at baseline and 6 months after completion of successful therapy. DNA methylation was also evaluated in TB patients with HIV and in healthy controls without Tuberculosis. 500ng of gDNA was bisulfite treated prior to running the Illumina Infinium MethylEPIC array
Project description:The differential expression of plasma miRNAs was analyzed in spinal tuberculosis patients and healthy volunteers using the Exiqon miRNA PCR array platform.
Project description:Osteoblast primary cell lines (OBS) from Shwachman-Diamond Syndrome (SDS) patients compared to healthy donors by one color transciptome array
Project description:Despite substantial investments, tuberculosis remains one of the biggest challenges in public health. DNA-immunotherapy is increasingly being suggested as a possibility to assist conventional treatment of tuberculosis. This strategy could allow treatment to be more efficient, faster and with advantages and modulate the host immune response, as demonstrated by our group with DNAhsp65 vaccine (Silva, Bonato et al., Gene Therapy, 2005). Based on this evidences, we performed a microarray assay to stydy the functional effects of DNAhsp65 immunotherapy associated with conventional chemotherapy in murine experimental tuberculosis. Briefly, we used a murine model of tuberculosis treatment compost by DNAhsp65 vaccine, or rifampicin and isoniazid or both therapies combined and performed a comprehensive analysis of its effects on gene expression of hostM-bM-^@M-^Ys lung . Female BALB/c mice,8 weeks old, were inoculated with 1.0 M-CM-^W 10e5 viable bacilli of Mycobacterium tuberculosis H37Rv strain by the intra-tracheal route in a level III bio-safety room facility (day 0). They were segregated in four groups, described below, with three animals each one. Control M-bM-^@M-^S just infected and not treated. Immunotherapy - Thirty days after challenge, 50 M-NM-<g of plasmid with DNA-insert (DNAhsp65) was administered by intramuscular injection in 50 M-NM-<L of 25% saccharose solution in saline into each quadriceps muscle, in four occasions, and at 10-days intervals, performing a final dose of 400 M-NM-<g of plasmid DNAhsp65 per animal. Control infected mice received saline. Chemotherapy - Thirty days after infection, animals were treated with water solution of isoniazid (25 mg/Kg, Sigma-Aldrich, St. Louis, MO, USA) and rifampicin (20 mg/Kg, Sigma-Aldrich, St. Louis, MO, USA) daily, during 30 days, by gavage. Control infected mice received the same volume of water. Association - The therapeutical association consists of the both therapeutical approaches, as described above. Ten days after the end of treatments, mice were killed by cervical dislocation under mild anesthesia, and lungs were removed to RNA extraction.
Project description:Investigation of whole genome gene expression of M. tuberculosis strain H37Rv:deltaRv3133c::pEXNF-3133c following ectopic expression of a plasmid-borne copy of wildtype Rv3133c compared the same strain with Rv3133c uninduced. The M. tuberculosis H37Rv:deltaRv3133c was originally described in Mol Microbiol. 2003 May; 48(3): 833–843.
